Whole blood treated with riboflavin and ultraviolet light: Quality assessment of all blood components produced by the buffy coat method

Transfusion

Volumn 55, Issue 4, 2015, Pages 815-823

  Schubert, Peter ^a,b,c   Culibrk, Brankica ^a,b   Karwal, Simrath ^a,b   Serrano, Katherine ^a,b,c   Levin, Elena ^a,b,c   Bu, Daniel ^a,b   Bhakta, Varsha ^a,d   Sheffield, William P ^a,d   Goodrich, Raymond P ^e   Devine, Dana V ^a,b,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e Scientific and Clinical Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PROTEIN S; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; VON WILLEBRAND FACTOR; ADENOSINE TRIPHOSPHATE; BLOOD CLOTTING FACTOR; GLUCOSE BLOOD LEVEL;

ARTICLE; BLOOD BUFFY COAT; BLOOD CLOTTING; BLOOD STORAGE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; HUMAN CELL; ILLUMINATION; IN VITRO STUDY; PARTIAL THROMBOPLASTIN TIME; PATHOGEN REDUCTION SYSTEM; PLASMA; PROTHROMBIN TIME; QUALITY CONTROL; THROMBOCYTE; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; ANALYSIS; BLOOD; BLOOD CELL; BLOOD SAFETY; BLOODBORNE BACTERIUM; CELL SIZE; CHEMISTRY; CRYOPRESERVATION; CYTOLOGY; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MEAN CORPUSCULAR VOLUME; MEMBRANE MICROPARTICLE; PHYSIOLOGY; PROCEDURES; RADIATION RESPONSE; THROMBOCYTE COUNT;

ADENOSINE TRIPHOSPHATE; BLOOD; BLOOD BUFFY COAT; BLOOD CELLS; BLOOD COAGULATION FACTORS; BLOOD GLUCOSE; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; CELL SIZE; CELL-DERIVED MICROPARTICLES; CRYOPRESERVATION; ERYTHROCYTE INDICES; HUMANS; PLASMA; PLATELET COUNT; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 84926472995     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12895     Document Type: Article

References (40)

1. Glynn SA, Busch MP, Dodd RY, et al. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion 2013; 53: 438-454.
2. Lozano M, Cid J,. Pathogen inactivation: coming of age. Curr Opin Hematol 2013; 20: 540-545.
3. Prowse CV,. Component pathogen inactivation: a critical review. Vox Sang 2013; 104: 183-199.
4. Seltsam A, Muller TH,. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162: 442-454.
5. Custer B, Agapova M, Martinez RH,. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2013; 50: 2461-2473.
6. Hervig T, Seghatchian J, Apelseth TO,. Current debate on pathogen inactivation of platelet concentrates-to use or not to use? Transfus Apher Sci 2010; 43: 411-414.
7. Cazenave JP, Folléa G, Bardiaux L, et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-2375.
8. Seghatchian J, Hervig T, Putter JS,. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates. Transfus Apher Sci 2011; 45: 75-84.
9. Prowse C,. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009; 23: 124-133.
10. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-1692.
11. Schubert P, Culibrk B, Coupland D, et al. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52: 397-408.
12. Bihm DJ, Ettinger A, Buytaert-Hoefen KA, et al. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C. Vox Sang 2010; 98: 108-115.
13. Klein HG, Glynn SA, Ness PM, et al. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009; 49: 1262-1268.
14. Rock G,. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100: 169-178.
15. Wagner SJ,. Developing pathogen reduction technologies for RBC suspensions. Vox Sang 2011; 100: 112-121.
16. Goodrich RP, Doane S, Reddy HL,. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20-30.
17. Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013; 53: 373-381.
18. Doane S, Keil SD, Gilmour DI, et al. Treatment of whole blood with riboflavin and UV light: effectiveness against clinically relevant bacterial contamination. Transfusion 2013; 53: 203A.
19. Keil SD, Rapaport R, Doane SK, et al. Viral reduction of intracellular HIV using the Mirasol system for whole blood. Vox Sang 2012; 103: 144.
20. Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012; 52: 409-416.
21. Tonnetti L, Thorp AM, Reddy HL, et al. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013; 53: 860-867.
22. El Chaar M, Atwal S, Freimanis GL, et al. Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013; 53: 3174-3183.
23. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51: 1460-1468.
24. Holme S,. In vitro assays used in the evaluation of the quality of stored platelets: correlation with in vivo assays. Transfus Apher Sci 2008; 39: 161-165.
25. Levin E, Culibrk B, Gyongyossy-Issa MI, et al. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production. Transfusion 2008; 48: 2331-2337.
26. Schubert P, Coupland D, Culibrk B, et al. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013; 53: 3164-3173.
27. Han V, Serrano K, Devine DV,. A comparative study of common techniques used to measure haemolysis in stored red cell concentrates. Vox Sang 2010; 98: 116-123.
28. Bhakta V, Jenkins C, Ramirez-Arcos S, et al. Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw. Transfusion 2013; 54: 418-425.
29. Sheffield WP, Bhakta V, Jenkins C, et al. Conversion to the buffy coat method and quality of frozen plasma derived from whole blood donations in Canada. Transfusion 2010; 50: 1043-1049.
30. Sheffield WP, Bhakta V, Talbot K, et al. Quality of frozen transfusable plasma prepared from whole blood donations in Canada: an update. Transfus Apher Sci 2013; 49: 440-446.
31. Heger A, Romisch J, Svae TE,. Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci 2005; 33: 257-267.
32. Serrano K, Chen D, Hansen AL, et al. The effect of timing of gamma-irradiation on hemolysis and potassium release in leukoreduced red cell concentrates stored in SAGM. Vox Sang 2014; 106: 379-381.
33. Morrell CN,. Immunomodulatory mediators in platelet transfusion reactions. Hematology Am Soc Hematol Educ Program 2011; 2011: 470-474.
34. Benjamin RJ, McLaughlin LS,. Plasma components: properties, differences, and uses. Transfusion 2012; 52 (Suppl 1): 9S-19S.
35. Coene J, Devreese K, Sabot B, et al. Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 2014; 54: 1321-1331.
36. Ettinger A, Miklauz MM, Hendrix BK, et al. Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18 degrees C. Transfus Apher Sci 2012; 46: 15-18.
37. Pidcoke HF, McFaul SJ, Ramasubramanian AK, et al. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time. Transfusion 2013; 53 (Suppl 1): 137S-149.
38. Kakaiya RM, Morse EE, Panek S,. Labile coagulation factors in thawed fresh frozen plasma prepared by two methods. Vox Sang 1984; 46: 44-46.
39. Council of Europe. Guide to the preparation, use and quality assurance of blood components. Strasbourg: Directorate for the Quality of Medicines & Health Care of the Council of Europe, 2011.
40. Tonnetti L, Proctor MC, Reddy HL, et al. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50: 1019-1027.